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Introduction: South Africa has the world’s largest antiretroviral treatment programme, which may contribute to 
the adverse drug reaction (ADR) burden. We aimed to determine the proportion of adult non-trauma emergency 
unit (EU) presentations attributable to ADRs and to characterise ADR-related EU presentations, stratified ac-
cording to HIV status, to determine the contribution of drugs used in management of HIV and its complications to 
ADR-related EU presentations, and identify factors associated with ADR-related EU presentation. 
Methods: We conducted a retrospective folder review on a random 1.7% sample of presentations over a 12-month 
period in 2014/2015 to the EUs of two hospitals in Cape Town, South Africa. We identified potential ADRs with 
the help of a trigger tool. A multidisciplinary panel assessed potential ADRs for causality, severity, and 
preventability. 
Results: We included 1010 EU presentations and assessed 80/1010 (7.9%) as ADR-related, including 20/239 
(8.4%) presentations among HIV-positive attendees. Among HIV-positive EU attendees with ADRs 17/20 (85%) 
were admitted, versus 22/60 (37%) of HIV-negative/unknown EU attendees. Only 5/21 (24%) ADRs in HIV- 
positive EU attendees were preventable, versus 24/63 (38%) in HIV-negative/unknown EU attendees. On 
multivariate analysis, only increasing drug count was associated with ADR-related EU presentation (adjusted 
odds ratio 1.10 per additional drug, 95% confidence interval 1.03 to 1.18), adjusted for age, sex, HIV status, 
comorbidity, and hospital. 
Conclusions: ADRs caused a significant proportion of EU presentations, similar to findings from other resource- 
limited settings. The spectrum of ADR manifestations in our EUs reflects South Africa’s colliding epidemics of 
infectious and non-communicable diseases. ADRs among HIV-positive EU attendees were more severe and less 
likely to be preventable.   
Introduction 
In South Africa, rapid scale-up of the HIV treatment programme is 
occurring within already overstretched and frequently understaffed 
health care facilities [1]. While the antiretrovirals currently included in 
South African guidelines are generally safe, and serious adverse drug 
reactions (ADRs) only occur in a small proportion of patients, the size of 
the treatment programme means that the absolute ADR burden may be 
considerable [2]. Strategies to minimize preventable harm should form a 
crucial part of such large-scale public health programmes; yet, in our 
setting, the burden of ADRs in general, and the burden of ADRs attrib-
utable to antiretroviral therapy (ART) specifically, is still largely un-
known [3]. 
The emergency unit (EU) provides an opportune environment in 
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which to study this burden: in South Africa, the EU forms the entry point 
into hospital for most patients, and resource limitations may result in 
even severely ill patients being managed fully in the EU, and not being 
admitted [4,5]. Hospital admission has been used to define an ADR as 
serious [6], but we considered that in a resource-limited setting EU 
presentation may also reflect serious ADRs. 
We aimed to determine the proportion of EU presentations at two 
hospitals in Cape Town, South Africa that were due to ADRs, stratified 
by HIV status. Secondary objectives were to describe the common ADR 
manifestations, their preventability, and the drugs most commonly 
implicated, stratified by HIV infection status; to describe the contribu-
tion of drugs used in the management of HIV infection and its compli-
cations to the burden of ADR-related EU presentations; and to identify 
factors associated with ADR-related EU presentations. 
Methods 
Study design and setting 
We retrospectively reviewed a random sample of adult (≥19 years) 
medical presentations to the EUs of two hospitals in Cape Town, South 
Africa over a twelve-month period. Groote Schuur Hospital (GSH) pro-
vides tertiary and secondary level care, and Khayelitsha District Hospital 
(KDH) is a district-level hospital, serving as a first point of referral for 
primary health care facilities in the district and providing a generalist 
level of care. Trends at the emergency unit of KDH have previously been 
published [4,5,7]. In 2015, the HIV prevalence among adults 15–49 
years old was 10.0% (95% confidence interval (CI) 7.9% to 11.9%) in 
the Western Cape province, of which Cape Town is the capital and 
largest city [8]. Programmatic guidelines implemented in December 
2014 recommended ART initiation at CD4 counts below 500 cells/μL 
with a fixed-dose-combination of tenofovir disoproxil fumarate (TDF), 
emtricitabine, and efavirenz the preferred first line therapy [9]. 
Fig. 1. Sampling strategy and exclusions applied. 
EU: emergency unit; GSH: Groote Schuur Hospital; ICD-10: International Statistical Classification of Diseases and Related Health Problems 10th Revision; KDH: 
Khayelitsha District Hospital. 
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Sample size calculation 
A previous study from a resource-limited setting, in Mumbai, India, 
found the proportion of ADR-related EU presentations to be 3.8% [10]. 
We calculated our sample size based on this proportion, using the z-score 
test for proportions in single populations: to detect a 3.8% proportion 
with 95% CI 1.8% to 5.8% a sample of 824 would be required. We 
planned to include ≥1000 presentations (500 per site), and over- 
sampled to allow for exclusions and missing records. 
Sampling and eligibility criteria 
We obtained an administrative data extract from each hospital of all 
adult presentations to the EU over the period 1 December 2014 to 30 
November 2015 (Fig. 1). At GSH, there were 31,898 presentations to the 
non-trauma EU over this period (the hospital has a separate trauma EU). 
At KDH, which has a single multidisciplinary EU, there were 27,333 EU 
presentations. From these we excluded 903 trauma-related pre-
sentations on the basis of the presence of ICD-10 codes S00-T35, T51- 
T79, T90-95, or V01-Y98 in the data, and included the remaining 26,430 
presentations in the KDH sampling frame. ICD-10 codes were frequently 
missing in the administrative data, and therefore we allowed pre-
sentations without ICD-10 codes into the sampling frame. 
We drew a simple random sample of 600 presentations at GSH, and a 
simple random sample of 628 presentations at KDH. We requested the 
medical records of the 1228 sampled presentations for folder review. We 
excluded sampled presentations if during folder review we found the 
patient was not an adult (i.e., incorrectly registered in the hospital in-
formation system) or if the patient presented to KDH EU for a trauma- 
related reason (i.e., trauma-related ICD-10 code was missing or incor-
rect). We also excluded presentations if the patient’s folder could not be 
found. 
Data sources and data collection methodology 
Each folder was reviewed collaboratively by a doctor-pharmacist 
pair. Data sources included clinical and nursing notes, discharge sum-
maries, bedside and laboratory investigation results, and prescription 
sheets. Electronic dispensing records were available for some patients; 
we used these to verify and augment the drug history contained in the 
folder. Doctor-pharmacist pairs used a trigger tool (Supplementary 
Table S1) adapted from Rozich [11] and previously used in our setting 
[12] to assist in identifying potential ADRs. Triggers were events, drug 
orders, or laboratory results suggestive of potential ADRs. 
Assessments and case definition 
A multidisciplinary panel (a clinical pharmacologist, a clinical 
pharmacist, a general physician, an EU physician, and the two doctors 
and two pharmacists who conducted the folder reviews) assessed each 
potential ADR for causality, severity, and preventability through 
consensus discussion. We used the Aronson and Ferner ADR definition 
[13], the World Health Organisation-Uppsala Monitoring Centre (WHO- 
UMC) system for standardised case causality assessment [14], Schumock 
and Thornton preventability criteria [15], and severity classification 
guidelines which we slightly modified from Temple [16] in these as-
sessments. Severity was classified (modification italicised) as (1) 
increased patient monitoring, but no patient harm; (2) treatment 
intervention, with temporary patient harm; (3) causing or contributing 
to the EU presentation, temporary patient harm; (4) permanent harm; (5) 
near-death; and (6) death. 
An ADR-related EU presentation was defined as a presentation with 
an ADR of severity level 3 or higher and causality assessment of 
‘possible’, ‘probable’, or ‘certain’. 
We classified ADRs as type A (predictable from the pharmacological 
action of the drug) or type B (idiosyncratic) according to the Rawlins and 
Thompson classification [17]. 
Analysis 
We calculated the drug count as the number of unique drugs used 
over the 30-day period before the EU presentation. Where we used 
electronic dispensing records (which contained the dispensed quantity 
without details on dose, dosing frequency, or duration) we considered 
any drug dispensed within 45 days before the presentation as being used 
during the 30-day window. 
We calculated a modified Charlson comorbidity score [18] for each 
presentation. Our modification excluded a diagnosis of HIV/AIDS from 
the calculation as the original score allocated to HIV/AIDS is inappro-
priately high in the ART era [19] and as we wanted to explore associ-
ation between HIV status and ADR-related presentation independently. 
We used cross-tabulation and chi-square statistics to explore associ-
ations between binary and categorical variables. We summarized 
continuous variables using medians and interquartile ranges, as they 
were not normally distributed, and used the Wilcoxon rank-sum test to 
compare the groups. We considered a P value of <0.05 to indicate sig-
nificant difference. 
We constructed a multivariate logistic regression model to explore 
associations between ADR-related EU presentation and age, sex, hospi-
tal, HIV infection status, ART status, drug count, and comorbidity score. 
We only included patients exposed to at least one drug in the model, and 
for those with multiple presentations, we only included first pre-
sentations. We stratified HIV infection and ART as follows: (1) HIV 
negative; (2) HIV status unknown; (3) HIV-positive, not on ART (or no 
documented evidence of ART); and (4) HIV-positive, on ART. Variables 
were selected for inclusion in the multivariate model a priori, at the time 
of study design, based on associations described previously [12,20,21]. 
We captured data into a purpose-built MS Access database (Micro-
soft, Redmond, WA). We analysed data using Stata version 13 (College 
Station, Texas, USA). 
Ethical considerations 
We retrospectively collected data through record review and did not 
approach patients, caregivers, prescribers, or physicians for any infor-
mation. We obtained ethics approval for this study from the University 
of Cape Town’s Human Research Ethics Committee (reference number 
845/2015), and received permission to conduct the study from the 
hospitals’ management. 
We shared anonymised data with the National Adverse Drug Event 
Monitoring Centre, which collects ADR reports on behalf of the South 
African medicines regulator. 
Results 
We included 1,010 EU presentations by 998 unique patients (Fig. 1), 
approximately 1.7% of the total number of presentations to the two EUs 
over the one-year period. Patient and presentation characteristics are 
summarised in Table 1; a stratification by site is given in Supplementary 
Table S2. Nearly one quarter of patients were known to be HIV-positive. 
Other common comorbidities were hypertension in 292/1,010 (29%), 
type 2 diabetes mellitus in 146/1,010 (14%), chronic kidney disease in 
63/1,010 (6.2%) and pulmonary tuberculosis in 45/1,010 (4.5%). Most 
presentations (645/1,010, 64%) were associated with a zero score on 
the modified Charlson comorbidity index, while only 84/1,010 (8.3%) 
scored 3 or higher. There was documented use of ≥ 1 drug(s) before 
606/1,010 (60%) presentations. Drug count ranged from 0 to 23. The 
most commonly used drugs are presented in Supplementary Table S3. 
Most EU presentations were for infectious diseases, including 52 (5.1%) 
for lower respiratory tract infections, 42 (4.2%) for tuberculosis, 31 
(3.1%) for urinary tract infections, and 30 (3.0%) for infectious 
gastroenteritis. Epilepsy/seizures (31 presentations, 3.1%), heart failure 
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(23, 2.3%), non-specific abdominal / pelvic pain (21, 2.1%), chronic 
obstructive pulmonary disease (20, 2.0%), chest pain (20, 2.0%), 
headache (16, 1.6%), and backache (14, 1.4%) were other common 
reasons for presenting. 
The multidisciplinary panel confirmed 80/1010 (7.9%) EU pre-
sentations to be ADR-related (95% CI 6.3% to 9.8%). The five most 
common ADRs are described in Fig. 2. Patients with ADR-related pre-
sentations appeared to be more often admitted than others (Table 1) 
although this did not reach statistical significance (p = 0.067). ADR- 
related EU presentations did result in longer hospital stays than other 
presentations (Table 1, p = 0.030). 
ADRs in HIV-positive EU attendees 
Among HIV-positive EU attendees there were 20/239 (8.4%) ADR- 
related EU presentations (Table 2). Drugs used in the management of 
HIV and its complications were implicated in 13 of these presentations: 
six for drug-induced renal impairment with TDF and/or rifampicin, four 
for drug-induced liver injury with efavirenz and/or antituberculosis 
treatment, three for diarrhoea with ritonavir-boosted lopinavir, and one 
for efavirenz-associated headache. 
The median age of HIV-positive EU attendees with ADR-related 
presentations was 39 years [IQR 33 to 46 years]. Thirteen of 21 (62%) 
ADRs were classified as type A (predictable from the pharmacological 
action of the drug) and 8/21 (38%) as type B (idiosyncratic). None of the 
ADRs in this patient group was fatal or near-fatal. Five of 21 (24%) were 
preventable: in all 5 cases, the implicated drugs were inappropriate for 
the patients’ condition (Supplementary Table S4). Regarding outcomes, 
we found that one patient (1/20, 5%) was discharged home from the EU, 
2/20 (10%) were transferred out to other facilities, and 17/20 (85%) 
were admitted to longer-stay hospital wards for a median [IQR] duration 
8 [3 to 15] days. 
ADRs in HIV-negative EU attendees and attendees with unknown HIV 
status 
There were 60/771 (7.8%) ADR-related presentations in this patient 
group (Supplementary Table S5). Nine presentations were for gastritis 
with non-steroidal anti-inflammatories, eight for hypoglycaemia with 
insulin and/or oral hypoglycaemic agents, and seven for upper gastro-
intestinal bleeds with non-steroidal anti-inflammatories. 
The median age of this group of EU attendees with ADR-related 
presentations was 62 years [IQR 47 to 74 years]. Fifty-nine of 63 
(94%) ADRs were classified as type A and 4/63 (6.3%) as type B. One 
ADR was fatal (an elderly man who presented with cardiac failure 
exacerbation following a large increase in carvedilol dose) and another 
was nearly fatal. Twenty-four of 63 (38%) were preventable, most often 
(17/24, 71%) because the implicated drugs were inappropriate for the 
patients’ condition (Supplementary Table S4). Thirty-six patients in this 
Table 1 
Characteristics of patients and first presentations (n = 998) to two EUs in Cape Town, South Africa, 2014–2015.   
n All patients Patients with first EU presentation  
ADR-related (n = 78) 
Patients with first EU presentation not  
ADR-related (n = 920) 
Age – median [IQR] (years)  998 44 [31 to 61] 55 [40 to 72] 43 [30 to 59] 
Age 19–39 years  
998 
434/998 (43%) 18/78 (23%) 416/920 (45%) 
Age 40–59 years 307/998 (31%) 26/78 (33%) 281/920 (31%) 
Age 60–79 years 219/998 (22%) 30/78 (38%) 189/920 (21%) 
Age ≥80 years 38/998 (3.8%) 4/78 (5.1%) 34/920 (3.7%) 
Sex – proportion female  992a 562/992 (57%) 49/78 (63%) 513/914 (56%) 
HIV-positive  
998 
234/998 (23%) 19/78 (24%) 215/920 (23%) 
HIV-negative 283/998 (28%) 14/78 (18%) 269/920 (29%) 
HIV status unknown 481/998 (48%) 45/78 (58%) 436/920 (47%) 
Presentations resulting in admission  998 377/998 (38%) 37/78 (47%) 340/920 (37%) 
Presentations ending in death  998 43/998 (4.3%) 3/78 (3.8%) 40/920 (4.3%) 
Duration of EU stay – median [IQR] (days)  967b 1 [1 to 2] 1 [1 to 2] 1 [1 to 2] 
Duration of total hospital stay – median [IQR] (days)  910c 2 [1 to 5] 2 [1 to 7] 2 [1 to 5] 
Drug count before presentation – median [IQR] (n drugs)  998 1 [0 to 4] 5 [3 to 9] 1 [0 to 4] 
Modified Charlson score – median [IQR]  998 0 [0 to 1] 1 [0 to 2] 0 [0 to 1] 
ADR: adverse drug reaction; EU: emergency unit; IQR: interquartile range. 
a Sex missing for 6 patients. 
b Duration of EU stay missing for 31 presentations. 
c Duration of total hospital stay missing for 88 presentations. 
Fig. 2. Frequency of the five most common adverse drug reaction-related 
presentations to two emergency units in Cape Town, South Africa, 2014–2015. 
DILI: drug-induced liver injury; GI: gastrointestinal. 
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group (36/60, 60%) were discharged home from the EU, 22/60 (37%) 
were admitted to longer-stay hospital wards, 1/60 (1.7%) left the EU of 
their own volition, and 1/60 (1.7%) had missing exit information. The 
22 admissions were of median [IQR] duration 7 [4 to 10] days. 
Factors associated with ADR-related presentation to the EU 
In the bivariate analysis we found associations between ADR-related 
EU presentation and age, hospital, drug count, and HIV/ART status. 
In the multivariate model we included 596 presentations: in 404/ 
1,010 EU presentations (40%) there was no documented drug exposure 
before the presentation, and ten remaining presentations were repeat 
presentations. In the multivariate analysis only an increasing drug count 
was independently associated with ADR-related presentation (Table 3). 
A sensitivity analysis, considering only HIV status and not ART status, 
showed similar results (Supplementary Table S6). 
Discussion 
ADRs constituted a significant proportion of the non-trauma burden 
in two EUs in our setting: there were more ADR-related presentations 
(7.9% of EU presentations) than presentations for lower respiratory tract 
infections, or for tuberculosis. Considering our resource limitations, it is 
important to note that patients presenting to the EU for ADRs stayed in 
hospital longer than patients presenting for other medical reasons, and 
that about one-third of these ADR-related EU presentations may have 
been avoided through more appropriate prescribing. With HIV a major 
public health problem in South Africa, we wanted to determine the 
relative contribution of drugs used in the management of HIV and its 
complications to the burden of ADR-related EU presentations, and found 
that these drugs were implicated in 13/80 (16%) ADR-related EU 
presentations. 
The proportion of ADR-related EU presentations was similar among 
HIV-positive and HIV-negative/unknown EU attendees (8.4% and 7.8%) 
and in our multivariate logistic regression analysis, HIV infection was 
not independently associated with ADR-related EU presentation. 
Table 2 
Details of adverse drug reaction-related presentations to two emergency units in Cape Town, South Africa, 2014–2015, among 20 HIV-positive emergency unit 
attendees.  
Age (y) Sex ADR description Type Causality Implicated drug/s Preventable 
45 M Hypoglycaemia A Certain Gliclazide Yes 




40 M Diarrhoea A Possible Lopinavir/ritonavir Yes 
40 M Diarrhoea A Probable Lopinavir/ritonavir No 
45 F Diarrhoea A Probable Lopinavir/ritonavir No 
60 F Constipation A Certain Tramadol Yes 
33 F Constipation A Certain Tramadol No 
47 M Upper gastrointestinal haemorrhage A Probable Acetylsalicylic acid No 
34 F Upper gastrointestinal haemorrhage A Probable Ibuprofen Yes 
28 M Headache A Possible Efavirenz No 
33 F Hepatocellular DILI B Possible Efavirenz No 
38 F Hepatocellular DILI B Certain Efavirenz No 
32 F Cholestatic DILI B Certain Efavirenz No 
45 F 
Mixed DILI 
B Probable Cotrimoxazole No 
B Possible Efavirenz No 
B Possible Isoniazid No 
B Possible Pyrazinamide No 
B Possible Rifampicin No 
Acute kidney injury 
B Possible Cotrimoxazole No 
B Possible Rifampicin No 
B Possible Tenofovir disoproxil No 
58 F Renal failure A Possible Tenofovir disoproxil No 
36 M Acute kidney injury A Possible Tenofovir disoproxil No 
39 M Acute-on-chronic kidney injury 
A Possible Tenofovir disoproxil No 
B Possible Ciprofloxacin No 
B Possible Diclofenac Yes 
B Possible Ibuprofen No 
28 M Acute kidney injury B Possible Rifampicin No 
49 M Acute kidney injury B Possible Rifampicin No 
38 F Abnormal uterine bleeding A Probable Norethisterone No 
ADR: adverse drug reaction; DILI: drug-induced liver injury; EU: emergency unit; F: female; M: male; y: years. 
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However, our study was not powered to detect such an association, and 
we nevertheless found substantial differences in the presentation, 
severity, and preventability of ADRs when comparing these two groups 
of patients. HIV-positive individuals were younger, and were more likely 
to present with type B (idiosyncratic) ADRs, which were less likely to be 
preventable. These frequently included kidney and liver injuries 
attributable to ART and antituberculosis treatment. In contrast, in-
dividuals who were HIV-negative or had unknown HIV status were 
older, and more likely to present with type A ADRs, predictable from the 
pharmacological action of the drugs involved, and therefore often pre-
ventable. Typical ADRs in this group of patients included gastritis and 
upper gastrointestinal bleeds attributable to non-steroidal anti-in-
flammatories, and hypoglycaemia attributed to insulin and oral hypo-
glycaemic agents. It is also notable that ADRs affecting the HIV-positive 
group were seemingly more severe, as 85% of this patient group were 
admitted into longer-stay wards versus only 37% of the HIV-negative/ 
unknown EU attendees presenting with ADRs. 
The proportion of non-trauma EU presentations that were attributed 
to ADRs in our study (7.9%) was higher than those from two studies 
from India (which found 3.8% [10] and 2.6% [22] respectively) but 
agrees with findings from similar studies in other resource-limited set-
tings: around 10% in Brazil [23], Malaysia [24], and Thailand [25], and 
5.9% in Turkey [26]. The Thai study [25] assessed preventability by the 
same criteria we did, and found a higher proportion of preventable ADRs 
(49%) than our study (35%). This difference may be due to differences in 
methodology: the Thai investigators interviewed patients whereas we 
conducted a folder review, which may have missed some preventability 
factors. There is little data on burden of ADRs resulting in EU presen-
tation in South Africa. A prospective study of elderly patients (≥65 
years) presenting to the GSH EU was conducted in 2005: an adverse drug 
event (ADE) contributed to the EU presentation of one in five patients in 
that study [27]. In that elderly study population, higher drug count was 
the only factor associated with ADE-related EU presentation on multi-
variate analysis, similar to our finding [27]. 
Our study has limitations. We were unable to obtain the folders of 
80/1228 (6.5%) randomly sampled presentations, especially at GSH, 
which might have introduced bias. Furthermore, information on clinical 
presentation and drug history came from contemporaneous notes made 
by clinicians in the patient folder. We attempted to reduce this limitation 
by supplementing data with electronic laboratory and dispensing data 
where possible. Nevertheless, we may have missed some ADR-related 
EU presentations due to missing information. HIV status was unknown 
in nearly half of all EU presentations, and only 136/239 (57%) HIV- 
positive EU attendees had ART documented in the folder. For the 
remaining 43%, our study design did not allow distinguishing between 
those truly not engaged in care, those who did not qualify for ART under 
guidelines then in use, and those whose ART was just not documented 
during the EU presentation. Better ART documentation may have 
increased the number of ADRs identified. In addition to misclassification 
of outcomes, missing HIV and ART data may have influenced the esti-
mates in our multivariate model, and limit the robustness of our findings 
related to HIV. As our study was limited to medical EU presentations, we 
missed trauma presentations precipitated by ADRs such as arrhythmia, 
syncope, altered mental status, etc. While data extractors may have been 
inaccurate or biased in their ascertainment of potential ADRs, data 
extraction was done by multidisciplinary pairs, and we used a trigger 
tool to aid potential ADR identification to minimize these inaccuracies 
and bias. We acknowledge that causality, severity, and preventability 
assessment of ADRs is inherently subjective; we attempted to reduce this 
subjectivity by conducting these reviews through a multidisciplinary 
panel discussion of each case. Future prospective studies which incor-
porate patients’ views and their social data would greatly enrich the 
understanding of factors predisposing to the development of ADRs. 
Our results may be generalizable to other district to tertiary level 
settings with similar disease burden and drug use patterns, and have 
important implications for clinicians and policymakers. First, we have 
clearly demonstrated an independent strong association between drug 
count and the occurrence of adverse drug reactions. Clinicians working 
in emergency units should always have a high index of suspicion for 
ADRs, but particularly so as the number of drugs a patient takes in-
creases. Second, for all prescribers and dispensing pharmacists, we 
highlight that the most common preventability factor was injudicious 
prescribing of the drug in question: either an inappropriate drug was 
prescribed, or a dose that was inappropriate was prescribed. Closer 
adherence to drugs’ regulated indications, contraindications, and dosing 
information is required, and serious consideration should be given to 
implementing intelligent prescription decision support systems to avoid 
errors. Moreover, improving patient education on ADRs and improving 
routine monitoring for ADRs within the HIV programme is important for 
earlier detection of ADRs, should they occur. 
Table 3 
Results of logistic regression model (n = 596 presentations) exploring associations with ADR-related EU presentation in Cape Town, South Africa, 2014–2015.  
Variable n Crude Adjusteda 
Odds ratio (95% CI) p-Value Odds ratio (95% CI) p-Value 
Sex 
Female  352 Referent Referent 
Male  244 0.834 (0.510 to 1.36) 0.46 0.889 (0.534 to 1.48) 0.65  
Age 
Per additional decade 596 1.25 (1.09 to 1.43) 0.001 1.18 (0.992 to 1.41) 0.06  
HIV and ART status 
Negative  170 Referent Referent 
Unknown  261 2.32 (1.23 to 4.38)  0.009 1.87 (0.934 to 3.76)  0.08 
Positive, no ART  33 1.11 (0.302 to 4.12)  0.87 1.68 (0.433 to 6.49)  0.46 
Positive and on ART  132 1.54 (0.721 to 3.27)  0.27 2.17 (0.934 to 5.02)  0.07  
Hospital 
GSH  339 Referent Referent 
KDH  257  0.508 (0.303 to 0.851)  0.010 0.690 (0.357 to 1.33) 0.27  
Drug count 
Per additional drug 596 1.13 (1.06 to 1.19) <0.001 1.10 (1.03 to 1.18) 0.005  
Modified Charlson comorbidity score 
Per additional point  596 1.22 (1.02 to 1.46) 0.03 0.990 (0.786 to 1.25) 0.93 
ADR: adverse drug reaction; ART: antiretroviral therapy; CI: confidence interval; EU: emergency unit; GSH: Groote Schuur Hospital; KDH: Khayelitsha District 
Hospital. 
a Adjusted for other predictor variables in the model. 
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While drugs used in the management of HIV and its complications 
contributed only a small number of ADRs in this study, the ADRs seen 
with these drugs were often severe and unavoidable. Quantifying these 
severe harms is important and our study demonstrates that it is feasible 
to collect this type of pharmacovigilance data in resource-constrained 
settings. The methodology developed is suitable for scaling in order to 
improve surveillance coverage, and can be periodically repeated. 
Repeated studies using this methodology may facilitate detection of 
changes in the pattern or burden of ADR-related harm associated with 
expansion of or changes to public health treatment programmes. 
Supplementary data to this article can be found online at https://doi. 
org/10.1016/j.afjem.2020.10.010. 
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